Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics program
暂无分享,去创建一个
Casey Lynnette Overby | Kristin A. Maloney | Mark D Kelemen | A. Shuldiner | P. McArdle | R. Horenstein | A. Beitelshees | T. Pollin | K. Maloney | M. Blitzer | R. Pakyz | Patrick F McArdle | Alan R Shuldiner | C. L. Overby | Amber L Beitelshees | Toni I Pollin | Richard B Horenstein | Richard Y Zhao | M. Kelemen | Kathleen Palmer | Ruth E Pakyz | Tameka D Alestock | Kristin A Maloney | Courtney O'Neill | Shaun Bhatty | Jamie Schub | Shawn W Robinson | Miriam G Blitzer | Lawrence Brown | Linda Jo Bone Jeng | Nicholas Ambulos | Mark R Vesely | M. Vesely | S. W. Robinson | N. Ambulos | Shaun Bhatty | K. Palmer | R. Y. Zhao | T. Alestock | Lawrence Brown | Jamie A. Schub | Ruth E. Pakyz | Tameka D. Alestock | Courtney O'Neill | Linda J. B. Jeng | C. Overby | Kathleen Palmer | Courtney O'Neill
[1] Dan M. Roden,et al. Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.
[2] Alan R. Shuldiner,et al. Pharmacogenomics of Anti-platelet Therapy: How much evidence is enough for clinical implementation? , 2013, Journal of Human Genetics.
[3] S. Scott,et al. Antiplatelet drug interactions with proton pump inhibitors , 2014, Expert opinion on drug metabolism & toxicology.
[4] Sarah H. Stephens,et al. Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy , 2013, Current Cardiology Reports.
[5] A. Bura,et al. 2 C 19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects , 2006 .
[6] T. Klein,et al. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.
[7] E. Antman,et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.
[8] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[9] J. Mega,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[10] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[11] J. O’Connell,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.
[12] Kristin A. Maloney,et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation , 2013, Clinical pharmacology and therapeutics.
[13] Laura Mauri,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[14] Kevin P. Bliden,et al. Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.
[15] S. Iturria,et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.
[16] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.
[17] Jeanette J McCarthy,et al. Genomic Medicine: A Decade of Successes, Challenges, and Opportunities , 2013, Science Translational Medicine.
[18] M. Relling,et al. Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.
[19] A. Beitelshees,et al. Cost‐Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel , 2012, Pharmacotherapy.
[20] T. Klein,et al. Clopidogrel: A Case for Indication‐Specific Pharmacogenetics , 2012, Clinical pharmacology and therapeutics.
[21] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.
[22] A. Bura,et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.
[23] Deepak L. Bhatt,et al. Antiplatelet therapy and proton pump inhibition: cause for concern? , 2012, Current opinion in cardiology.
[24] E. Clayton,et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.
[25] Julie A Johnson,et al. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. , 2013, Pharmacogenomics.
[26] Xiang Ma,et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. , 2013, International journal of cardiology.
[27] E. Rampersaud,et al. Identification of Novel Candidate Genes for Type 2 Diabetes From a Genome-Wide Association Scan in the Old Order Amish , 2007, Diabetes.
[28] J. Ferrières,et al. Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.
[29] R. Weinshilboum,et al. Challenges in Implementing Genomic Medicine: The Mayo Clinic Center for Individualized Medicine , 2013, Clinical pharmacology and therapeutics.
[30] J. O’Connell,et al. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.
[31] L Gong,et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.